AtriCure ATRC 深 沪
等待开盘 07-18 09:30:00 美东时间
29.75
-0.630
-2.07%
华盛通- 最 高30.69
- 今 开30.40
- 成交量 40.98万股
- 最 低 29.60
- 昨 收 30.38
- 总市值 14.73亿
- 52周最高 43.11
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 20.20
- 委 比 92.08%
- 总股本 4950.49万
- 历史最高 89.18
- 量 比 1.02
- 振 幅 3.59%
- 历史最低 5.90
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AtriCure Completes Enrollment In Left Atrial Appendage Exclusion For Prophylactic Stroke Reduction Clinical Trial
Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without
07-15 20:05
AtriCure’s Strong Q1: Revenue Growth and Challenges
Atricure, Inc. (($ATRC)) has held its Q1 earnings call. Read on for the main hi...
05-01 08:25
AtriCure, Inc. Reports Strong Q1 2025 Growth
Atricure, Inc. ( ($ATRC) ) has released its Q1 earnings. Here is a breakdown of...
04-30 12:25
AtriCure Earnings Preview
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on T...
04-29 03:02
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $52
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $66 to $52.
03-28 19:30
美股大行评级 | 潜在涨幅345.1%！Corvus Pharma获Oppenheimer升目标价至15美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112300378952404993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Corvus Pharma(CRVS)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至"超配"，目标价从
03-28 09:06
AtriCure Highlights Growth and Innovation at Investor Day
Atricure ( ($ATRC) ) has provided an announcement. On March 26, 2025, AtriCure,...
03-27 01:28
美股大行评级 | 高盛：上调Adaptive Biotechnologies评级至"买入"，目标价从8美元升至9美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1110125309827231744.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Amprius Technologies(AMPX)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 韦德布什：维持Monte Rosa Therapeutics(GLUE)"跑
03-24 07:31
